Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ieven, M.
Right arrow Articles by Goossens, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ieven, M.
Right arrow Articles by Goossens, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 45, 51
© 2000 The British Society for Antimicrobial Chemotherapy

In vitro activity of gemifloxacin compared with other antimicrobial agents against recent clinical isolates of streptococci

Margareta Ieven*, Wendy Goossens, Stefan De Wit and Herman Goossens

Laboratory for Microbiology, University Hospital Antwerp, Wilrijkstraat 10, B-2650 Edegem, Belgium

This study investigated the in vitro activity of gemifloxacin (SB-265805) against 50 recent clinical isolates of Streptococcus pyogenes, Streptococcus agalactiae and viridans streptococci using the microdilution method. This activity was compared with that of the quinolone agents ofloxacin, ciprofloxacin, levofloxacin, trovafloxacin and grepafloxacin, and with that of penicillin, ampicillin, clarithromycin and azithromycin. Gemifloxacin was significantly more potent than the other quinolones tested. Its potency was equal to that of penicillin for S. agalactiae, and superior to that of penicillin for viridans streptococci. The MIC50 of gemifloxacin for S. pyogenes (0.015 mg/L) was equal to that of penicillin, with an MIC90 of 0.03 mg/L. Gemifloxacin was also active against isolates of S. agalactiae (MIC = 0.03–0.06 mg/L) and S. pyogenes (MIC = 0.03– 0.06 mg/L) with reduced susceptibility to ofloxacin (MIC = 4–8 mg/L) and grepafloxacin (MIC = 4 mg/L). These preliminary observations indicate that gemifloxacin is a promising antimicrobial agent for clinical use.

* Corresponding author. Tel: +32-3821-3644; Fax: +32-3825-4281; E-mail: greet.ieven{at}uza.uia.ac.be


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
Y. Kawamura, H. Fujiwara, N. Mishima, Y. Tanaka, A. Tanimoto, S. Ikawa, Y. Itoh, and T. Ezaki
First Streptococcus agalactiae Isolates Highly Resistant to Quinolones, with Point Mutations in gyrA and parC
Antimicrob. Agents Chemother., November 1, 2003; 47(11): 3605 - 3609.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.